The Pet Industry Federation has launched a sector-wide member consultation this week to gather industry views on the potential future regulation of flea treatment products, containing fipronil and imidacloprid.

The issue has come about following the Veterinary Medicines Directorate (VMD) Call for Evidence, which is currently examining the environmental impact of certain parasiticide products and whether changes may be needed to how they are supplied and used.

PIF believes it is important that the practical realities faced by pet businesses and the wider impact on pet owners and animal welfare, are fully understood before any decisions are taken.

Potential changes could affect a range of businesses across the sector, including pet retailers, groomers and boarding establishments.

Questions remain over whether restrictions on access could shift sales away from specialist pet retailers, reduce convenience for owners seeking preventative treatment, or create knock-on effects for businesses dealing with untreated pets.

Nigel Baker, PIF CEO, said: “This is an important issue with implications for businesses, pet owners and animal welfare. It is essential that policymakers hear from those working directly with pets and pet owners every day. We want to understand members’ views, concerns and practical experiences so that we can represent the sector in a balanced and constructive way.”

PIF has launched separate surveys for its members including pet retailers, groomers and boarding establishments, with findings helping to shape its response and wider discussions with industry stakeholders.

Alongside gathering member evidence, PIF is also engaging with National Office of Animal Health as part of wider industry dialogue on the issue.

PIF believes owner education will be a key part of any long-term solution, helping ensure flea treatments are used responsibly while maintaining access to effective parasite control that supports pet welfare.

PIF members are encouraged to complete the relevant survey by Tuesday 5 May. The VMD Call for Evidence closes on 11 June. More information can be found here: https://consult.defra.gov.uk/vmd-policy-development-and-delivery-office/call-for-evidence-fipronil-imidacloprid/